Detalhe da pesquisa
1.
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.
Ann Oncol
; 34(11): 1003-1014, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37673211
2.
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Ann Oncol
; 34(10): 885-898, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37597578
3.
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.
Ann Oncol
; 30(11): 1821-1830, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31504139
4.
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Ann Oncol
; 29(7): 1541-1547, 2018 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29718092
5.
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830].
Ann Oncol
; 32(8): 1068, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34099371
6.
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Ann Oncol
; 30(11): 1842, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31407010
7.
Growth retardation and tumour inhibition by BRCA1.
Nat Genet
; 12(3): 298-302, 1996 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-8589721
8.
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.
NPJ Precis Oncol
; 6(1): 13, 2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35233056
9.
Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function.
J Cell Biol
; 153(5): 917-32, 2001 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-11381079
10.
Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression.
Oncogene
; 25(24): 3408-23, 2006 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-16186809
11.
Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
J Clin Invest
; 92(6): 2569-76, 1993 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-7504687
12.
Transforming growth factor alpha protection against drug-induced injury to the rat gastric mucosa in vivo.
J Clin Invest
; 90(6): 2409-21, 1992 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-1281834
13.
Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice.
J Clin Invest
; 84(5): 1418-23, 1989 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-2553774
14.
Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice.
Mol Cell Biol
; 16(10): 5726-36, 1996 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-8816486
15.
Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1.
Mol Biol Cell
; 12(11): 3328-39, 2001 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-11694570
16.
Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism.
Mol Biol Cell
; 12(1): 27-36, 2001 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-11160820
17.
Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta.
J Natl Cancer Inst
; 91(1): 46-53, 1999 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-9890169
18.
Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA.
J Natl Cancer Inst
; 89(5): 365-73, 1997 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-9060958
19.
Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia.
J Natl Cancer Inst
; 91(24): 2096-101, 1999 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-10601380
20.
Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice.
Cancer Res
; 56(5): 1098-1103, 1996 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-8640767